A possible contributor to erythropoiesis-stimulating agents requirement in hemodialysis: Paraoxonase 1 activity

Year 2021, , 116 - 122, 29.07.2021

Berfu Korucu , Hasan Hacı , Elif Burcu Bali , Mehmet Kürşat Derici , Galip Guz

https://doi.org/10.46310/tjim.882813

Abstract

Background: Anemia is one of the most prevalent complications of chronic kidney disease (CKD). In CKD-related anemia, circulating erythrocytes have a decreased life span. Paraoxonase-1 (PON1) activity is one of the essential factors protecting cell membranes, e.g., erythrocytes, from lipid peroxidation under normal conditions. In this study, we investigated PON1 activity in hemodialysis (HD) patients with and without erythropoiesis-stimulating agents (ESA) therapy and the possible relationship of PON1 activity levels with the ESA dose required.
Methods: This study is composed of patients undergoing HD with a minimum dialysis vintage of six months. We excluded cases with an active infection, cardiovascular events and malignancy, hypo- or hyperthyroidism, central venous catheters, iron deficiency, cystic kidney diseases, nephrectomy, and routine C-reactive protein (CRP) levels higher than reference range within the last six months.
Results: Baseline characteristics, laboratory parameters, oxidative stress, and systemic inflammatory indices were similar between groups. The mean PON1 activity of the ESA+ group was significantly lower than the ESA– group (191.4 ±118.8 and 488.1±174.9,respectively; p<0.001). Cumulative ESA doses and PON1 activity were significantly and negatively correlated (R=-0.736, p<0.001).
Conclusion: The results of this study suggest that lower PON1 activity in HD patients is associated with the requirement for ESA therapy, presumably due to decreased life span of erythrocytes. Further studies examining the relationship between PON1 activity and ESA treatment requirements are necessary to reveal new treatment goals for CKD-related anemia.

Keywords

Paraoxanase 1, erythropoiesis-stimulating agents, hemodialysis, anemia

References

• Stauffer ME, Fan T (2014) Prevalence of anemia in chronic kidney disease in the United States. PLoS One 9
• Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J (2018) Burden of anemia in chronic kidney disease patients in Japan: a literature review. Ther Apher Dial 22:444-56
• Zadrazil J, Horak P (2015) Pathophysiology of anemia in chronic kidney diseases: A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:197-202
• Wilmink J, Rosengarten P, Vet R, Goudsmit R (1982) Serum erythropoietin (ESF) titers in anemia of chronic renal failure. The Journal of laboratory and clinical medicine 100:720-34
• Ross RP, McCrea JB, Besarab A (1994) Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. ASAIO journal (American Society for Artificial Internal Organs: 1992) 40:M880-5
• Brimble KS, McFarlane A, Winegard N, Crowther M, Churchill DN (2006) Effect of chronic kidney disease on red blood cell rheology. Clin Hemorheol Microcirc 34:411-20
• Bissinger R, Artunc F, Qadri SM, Lang F (2016) Reduced erythrocyte survival in uremic patients under hemodialysis or peritoneal dialysis. Kidney Blood Press Res 41:966-77
• Glassock RJ (2008) Uremic toxins: what are they? An integrated overview of pathobiology and classification. J Ren Nutr 18:2-6
• Korol L (2015) MODELING IN VITRO PATHWAYS OF ACTIVATION OF LIPID PEROXIDATION AND PROTEIN IN CHRONIC KIDNEY DISEASE. Fiziolohichnyi zhurnal (Kiev, Ukraine: 1994) 61:92-97
• Rosenblat M, Vaya J, Shih D, Aviram M (2005) Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179:69-77 Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, Wagner MA, Besler C, Gerstenecker G (2013) Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. The Journal of clinical investigation 123:3815-28
• Ferretti G, Bacchetti T, Busni D, Rabini R, Curatola G (2004) Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. The Journal of Clinical Endocrinology & Metabolism 89:2957-62
• Motta S, Letellier C, Ropert M, Motta C, Thiébault J (2009) Protecting effect of vitamin E supplementation on submaximal exercise-induced oxidative stress in sedentary dogs as assessed by erythrocyte membrane fluidity and paraoxonase-1 activity. The Veterinary Journal 181:288-95
• Suematsu Y, Goto M, Park C, Nunes AC, Jing W, Streja E, Rhee CM, Cruz S, Kashyap ML, Vaziri ND (2019) Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients. The Journal of Clinical Endocrinology & Metabolism 104:4848-56
• Miljkovic M, Stefanovic A, Vekic J, Zeljkovic A, Gojkovic T, Simic-Ogrizovic S, Bogavac-Stanojevic N, Cerne D, Ilic J, Stefanovic I (2018) Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. Clinical biochemistry 60:52-58
• López-Gómez JM, Portolés JM, Aljama P (2008) Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality: New strategies to prevent cardiovascular risk in chronic kidney disease. Kidney Int 74:S75-S81
• Scott SD (2002) Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 22:160S-65S
• Shemin D, Bostom AG, Laliberty P, Dworkin LD (2001) Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38:85-90
• Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ (2011) Red blood cell survival in long-term dialysis patients. Am J Kidney Dis 58:591-98
• Ma J, Dou Y, Zhang H, Thijssen S, Williams S, Kuntsevich V, Ouellet G, Wong MM, Persic V, Kruse A (2017) Correlation between inflammatory biomarkers and red blood cell life span in chronic hemodialysis patients. Blood Purif 43:200-05
• Alonzi T, Mancone C, Amicone L, Tripodi M (2008) Elucidation of lipoprotein particles structure by proteomic analysis. Expert review of proteomics 5:91-104
• Hine D, Mackness B, Mackness M (2012) Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB life 64:157-61
• Singh K, Singh R, Chandra S, Tyagi S (2018) Paraoxonase-1 is a better indicator than HDL of atherosclerosis–A pilot study in North Indian population. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12:275-78
• BLATTER MC, James RW, MESSMER S, BARJA F, POMETTA D (1993) Identification of a distinct human high‐density lipoprotein subspecies defined by a lipoprotein‐associated protein, K‐45: Identity of K‐45 with paraoxonase. Eur J Biochem 211:871-79
• Mackness B, Durrington P, Boulton A, Hine D, Mackness M (2002) Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 32:259-64 Gbandjaba NY, Ghalim N, Hassar M, Berrougui H, Labrazi H, Taki H, Saile R, Khalil A (2012) Paraoxonase activity in healthy, diabetic, and hemodialysis patients. Clin Biochem 45:470-74
• Ribeiro S, do Sameiro Faria M, Mascarenhas-Melo F, Freitas I, Mendonça MI, Nascimento H, Rocha-Pereira P, Miranda V, Mendonça D, Quintanilha A (2012) Main determinants of PON1 activity in hemodialysis patients. Am J Nephrol 36:317-23
• Kirschbaum B (2004) Correlation Studies of Plasma Paraoxonase Activity and Uric Acid Concentration with AAPH‐Induced Erythrocyte Hemolysis in Hemodialysis Patients. Artif Organs 28:259-64
• Shunmoogam N, Naidoo P, Chilton R (2018) Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vascular health and risk management 14:137
• Mahrooz A, Mackness M, Bagheri A, Ghaffari-Cherati M, Masoumi P (2019) The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: The missing link between environmental and genetic regulation. Clin Biochem